|
1）Katakami N, Gemma A, Sakai H, et al. Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701). J Clin Oncol. 2012; 30: abstr 7515
|
|
|
|
|
2）Hirashima I, Okamoto H, Yoshioka, et al. Phase III study comparing the effects of carboplatin plus S-1 and carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer: An updated report of the LETS study (WJTOG3605). J Clin Oncol. 2011; 9: abstr 7552
|
|
|
|
|
|
3）Ichinose Y, Yoshimori K, Sakai H, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 2004; 10: 7860-4
|
|
|
|
|
4）Kubota K, Sakai H, Yamamoto N, et al. A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010; 5: 702-6
|
|
|
|
|
|
5）Okamoto I, Yoshioka H, Morita S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol. 2010; 28: 5240-6
|
|
|
|
|
|
6）Yoshioka H, Okamoto I, Morita S, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Ann Oncol. 2013; 24: 1326-31
|
|
|
|
|
|
7）Takeda M, Okamoto I, Hirabayashi N, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer. 2011; 73: 103-9
|
|
|
|
|
|
8）Mitsudomi T, Iwamoto Y, Nishio K, et al. Biomarker analysis of WJOG4107, a randomized phase II trial of adjuvant chemotherapy with S-1 versus CDDP+S-1 for resected stage II-IIIA non-small cell lung cancer (NSCLC). J Clin oncol. 2013; 17: abstr 7518
|
|
|
|
|
|
9）Fukushima M, Sakamoto K, Sakata M, et al. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep. 2010; 24: 1307-13
|
|
|
|
|
|
10）Kishino D, Nogami N, Segawa Y, et al. A phase II study of cisplatin (P), S-1 (S), and concurrent thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (LA-NSCLC): Okayama Lung Cancer Study Group trial 0501. J Clin oncol. 2012; 30: abstr 7042
|
|
|
|
|